Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03535675 · ClinicalTrials.gov registry record · Phase 3
Muscadine Plus (MPX) In Men With Prostate Cancer
A Phase 3 study, sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins.
- Terminated
- Registry status
- Phase 3
- Development phase
- 59
- Enrollment target
NCT03535675 is a Phase 3 study that was terminated before completion, run by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins. The registered enrollment target is 59 participants.
The verdict
NCT03535675, a Phase 3 study, was terminated before completion, sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 59 participants
- Enrollment target
Study Summary
This research is being done to determine if men with rising PSA after initial therapy for localized prostate cancer who display the Alanine/Alanine SOD2 genotype of MnSOD and supplement their diet with MPX have greater decrease in PSA slope following treatment compared to men that do not supplement with MPX.
Interventions
- DRUG Placebos
- DRUG Muscadine Plus
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 59 participants |
| Start Date | 2018-10-30 |
| Est. Completion | 2022-11-03 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03535675
The ClinicalTrials.gov registry entry for NCT03535675 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 59 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, which has 523 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebos is the first listed.
NCT03535675 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03535675 about?
NCT03535675 is a clinical study titled "Muscadine Plus (MPX) In Men With Prostate Cancer". This research is being done to determine if men with rising PSA after initial therapy for localized prostate cancer who display the Alanine/Alanine SOD2 genotype of MnSOD and supplement their diet with MPX have greater decrease in PSA slope following treatment compared to men that do not supplement ...
What is the current status of trial NCT03535675?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 59 participants. The study started on 2018-10-30. Estimated completion is 2022-11-03.
What interventions are being tested in trial NCT03535675?
The interventions under investigation include: Placebos (DRUG), Muscadine Plus (DRUG).
Who is sponsoring clinical trial NCT03535675?
This trial is sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, which has 523 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.